Healthcare and Pharmaceuticals INDUSTRIES

WilmerHale's lawyers offer exceptional experience assisting healthcare providers, healthcare insurers and the companies that supply them with specialized products and services across a broad range of specialties. These specialties include fraud investigations and litigation; data protection and privacy; patent and trademark prosecution and litigation; transactions; antitrust; regulatory, legislative and public policy counseling; and commercial litigation. Our lawyers also include leading healthcare practitioners in the EU and China.

The healthcare industry accounts for nearly one-fifth of the US economy. In the EU, healthcare spending is expected to rise to nearly 15% of GDP by 2030. Our lawyers—who include the former general counsel of one of the largest health insurers in the country and senior in-house lawyers from an array of life sciences companies—know the industry from the inside.  

Experience

With the adoption of the Affordable Care Act, the US healthcare system—and the legal regime governing it—are undergoing dramatic changes. Major regulatory innovations are also advancing overseas. Our lawyers bring experience serving in senior roles in government and hands-on knowledge of how the government works in advising clients on the many issues affecting healthcare companies that have a government component. Our group includes individuals who have served in the Justice Department, including in its Antitrust Division, the Federal Trade Commission, the White House and on the staffs of Senators who have been the leading voices on healthcare policy issues.

Our healthcare group brings together specialists in many fields of greatest use to companies and organizations in the healthcare sector:

  • Healthcare Investigations/Enforcement Litigation. WilmerHale has been involved in some of the most significant healthcare-related, criminal and civil investigations and litigation during the last decade. We frequently represent clients in investigations, leveraging the knowledge of our deep bench of former Justice Department officials, including two former Deputy Attorneys General, a former Assistant Attorney General in charge of the Civil Division, a former US Attorney and numerous Assistant US Attorneys.
  • Public Policy and Congressional & Executive Branch Investigations. Operating at the intersection of law, policy and politics, WilmerHale’s lawyers represent clients in high-stakes congressional and executive-branch investigations, help them shape legislation and regulations and guide them through the political and media mazes that often accompany public policy controversies.
  • Transactional and Corporate. WilmerHale’s lawyers are renowned for their work on mergers and acquisitions, IPO’s, private equity deals, strategic alliances and corporate governance matters both domestically and in the EU and China. We provide a one-stop source for solutions to the diverse array of corporate issues facing healthcare and life-sciences clients.
  • Patent and Trademark Prosecution and Litigation. WilmerHale’s patent litigation practice is second-to-none, garnering numerous national awards for consistently winning headline-grabbing cases. Our patent prosecution team has filed thousands of US and foreign patent applications. And our trademark lawyers are equally adept at registration and litigation.
  • Data Security and Privacy. Our firm offers significant experience navigating the complex waters of data security and privacy laws, including HIPAA, the HITECH Act and FTC medical data breach notification requirements. From advising on domestic and global regulatory issues to litigating nuanced questions of first impression, to shaping compliance regimes, our lawyers provide soup-to-nuts counsel to our clients.
  • Antitrust. Our antitrust and competition lawyers counsel companies on the full spectrum of antitrust issues in jurisdictions across the United States and around the globe. Our deep knowledge of securing merger clearance should put us at the top of the list for any healthcare company facing acquisition decisions.
  • Commercial Litigation. Our philosophy is simple: Consistent courtroom excellence is essential to client satisfaction in the resolution of high-stakes commercial disputes like the ones we litigate. We have extensive experience litigating a wide variety of complex civil cases, including ERISA matters.
  • EU/Germany. Advising on regulatory, public policy, and legal strategy questions in the German healthcare arena as well as in the rest of the European Union, our partners offer pharmaceutical companies, producers of medical devices, associations of physicians and other healthcare clients a full-services approach to tackling questions of public law, privacy, transactional, licensing, and other types of law as well as public policy and legal strategy advice.
  • China. WilmerHale offers companies around the world extensive experience and understanding of the Chinese legal and policy systems and their impact on the healthcare, pharmaceuticals and medical device industries. We also handle a wide range of acquisitions and other corporate transactions and provide unparalleled insight on market access questions.

Publications & News

View

April 26, 2017

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors.

April 25, 2017

WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

Aquinnah Pharmaceuticals announced that Pfizer Inc. and AbbVie Inc. have invested in their work to treat Amyotrophic Lateral Sclerosis, Alzheimer's disease and other neurodegenerative diseases.

April 19, 2017

President Trump Signs Buy American and Hire American Executive Order

On April 18, 2017, President Trump signed an important executive order promoting “Buy American” and “Hire American” policies.

April 3, 2017

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately-held rare disease company, today announced that Sucampo has acquired Vtesse for upfront consideration of $200 million.

March 31, 2017

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

March 30, 2017

WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners.

March 16, 2017

Allergan and Editas Medicine Enter Into Strategic R&D Alliance

The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform.

February 24, 2017

Amygdala Neurosciences Acquires GS-6637 From Gilead Sciences

On February 16, Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, announced that it entered into an agreement with Gilead Sciences, Inc.

February 24, 2017

Form SHC Deadline Approaching for Investment Advisers and Other Reporters

Investment advisers should take note that they may be required to file Treasury International Capital Benchmark (TIC) Form SHC by Friday, March 3, 2017.

February 14, 2017

WilmerHale Counsels Cynosure in $1.65B Acquisition by Hologic

The WilmerHale team on the transaction was led by Hal Leibowitz and Jason Kropp and included Andrew Bonnes, Kim Wethly, Leon Greenfield, Bruce Manheim, Steve Barrett, Laura Schneider, Amy Null, Julie Hogan Rodgers, Ciara Baker, Davis Sluis, Caroline Dotolo and Alex Civetta.